Innovent Biologics

Innovent Biologics To empower patients worldwide with affordable, high-quality biopharmaceuticals Innovent has launched 17 products in the market.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Happy Holidays from our team! Thank you to our partners, colleagues, and community for your trust and support throughout...
25/12/2025

Happy Holidays from our team! Thank you to our partners, colleagues, and community for your trust and support throughout the year. We look forward to continuing our shared progress and collaboration in the year ahead.

We are thrilled to share that TABOSUN® (ipilimumab N01 injection), China's first domestic anti-CTLA-4 antibody, has rece...
25/12/2025

We are thrilled to share that TABOSUN® (ipilimumab N01 injection), China's first domestic anti-CTLA-4 antibody, has received NMPA approval in combination with TYVYT® for the neoadjuvant treatment of patients with stage IIB–III resectable MSI-H/dMMR colon cancer.

This dual-immunotherapy regimen demonstrated strong improvements in pathological complete response and enabled many patients to avoid additional postoperative chemotherapy. The approval addresses an important gap in early-stage treatment and expands meaningful options for patients and clinicians. As Innovent's 18th approved product, TABOSUN® reflects the continued growth of our immuno-oncology portfolio and underscores our long-term commitment to developing high-quality therapies that advance standards of care and benefit patients worldwide. https://www.prnewswire.com/news-releases/chinas-first-domestic-anti-ctla-4-monoclonal-antibody-innovents-tabosun-ipilimumab-n01-injection-received-nmpa-approval-302649444.html

We're excited to share that our latest research has been published in Nature. The DREAMS-1 and DREAMS-2 Phase 3 studies ...
18/12/2025

We're excited to share that our latest research has been published in Nature. The DREAMS-1 and DREAMS-2 Phase 3 studies of mazdutide in Chinese adults with type 2 diabetes appeared back-to-back as Accelerated Article Previews, adding to the growing body of evidence supporting China-led innovation in metabolic disease research. https://www.prnewswire.com/news-releases/nature--two-phase-3-clinical-results-of-mazdutide-glp-1gcg-dual-receptor-agonist-in-chinese-adults-with-type-2-diabetes-have-been-back-to-back-published-in-nature-302644606.html

The Phase 1b study of mazdutide in Chinese adolescents with obesity met its primary endpoint, delivering meaningful BMI ...
15/12/2025

The Phase 1b study of mazdutide in Chinese adolescents with obesity met its primary endpoint, delivering meaningful BMI and weight reductions along with broad metabolic improvements in just 12 weeks. With a clean safety profile and no approved treatment options currently available for young people in China, this marks a significant step forward for an area of urgent unmet need. A Phase 3 trial is on the way, moving this potential therapy into its next chapter.

https://en.prnasia.com/releases/global/mazdutide-demonstrates-significant-weight-loss-and-metabolic-benefits-in-phase-1b-clinical-trial-in-chinese-adolescents-with-obesity-515786.shtml

The first patient has been dosed in the Phase 1 trial of IBI3011, Innovent’s monoclonal antibody targeting IL-1RAP. This...
15/12/2025

The first patient has been dosed in the Phase 1 trial of IBI3011, Innovent’s monoclonal antibody targeting IL-1RAP. This study explores a potential new option for patients with gout flares, a condition that affects millions in China and often lacks effective, targeted treatments. We’re excited to take this first step toward therapies that could change how gout is managed. https://en.prnasia.com/releases/global/innovent-announces-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3011-a-recombinant-anti-human-interleukin-1-receptor-accessory-protein-monoclonal-antibody-515430.shtml

We’re pleased to share that PECONDLE® (picankibart injection) has successfully met both primary and key secondary endpoi...
15/12/2025

We’re pleased to share that PECONDLE® (picankibart injection) has successfully met both primary and key secondary endpoints in the Phase 3 CLEAR-2 study, reinforcing its role in delivering durable, long-term management for moderate-to-severe psoriasis. With its recent NMPA approval as China’s first self-developed IL-23p19 monoclonal antibody, PECONDLE® represents an important step forward in bringing reliable, long-lasting treatment options to patients. https://en.prnasia.com/releases/global/innovent-announces-pecondle-picankibart-injection-phase-3-study-clear-2-meets-endpoints-delivering-superior-long-term-management-solution-for-moderate-to-severe-psoriasis-515212.shtml

At ASH 2025, Innovent shared the first clinical results of IBI3003, our novel trispecific antibody designed to simultane...
08/12/2025

At ASH 2025, Innovent shared the first clinical results of IBI3003, our novel trispecific antibody designed to simultaneously target GPRC5D, BCMA and CD3 for relapsed or refractory multiple myeloma. The initial data show promising tolerability and early efficacy signals, even in high-risk and heavily pretreated patients. IBI3003 continues to advance in an ongoing Phase 1/2 study across China and Australia. https://www.prnewswire.com/news-releases/ash-2025-oral-presentation-innovent-biologics-announces-initial-results-of-the-first-in-human-phase-1-study-of-trispecific-antibody-ibi3003-in-relapsed-or-refractory-multiple-myeloma-302634871.html



We're happy to share the seven Innovent medicines across immunotherapy and targeted oncology have been included in China...
08/12/2025

We're happy to share the seven Innovent medicines across immunotherapy and targeted oncology have been included in China's 2025 National Reimbursement Drug List. This update features a new indication for TYVYT® and the first-time inclusion of SYCUME® and several other innovative therapies, all set to take effect on January 1, 2026. https://www.prnewswire.com/news-releases/innovent-announces-inclusion-of-seven-innovative-drugs-including-tyvyt-new-indication-and-sycume-in-chinas-national-reimbursement-drug-list-302634711.html

Exciting news! Innovent has received NMPA approval for PECONDLE® (picankibart injection), China's first domestic IL-23p1...
02/12/2025

Exciting news! Innovent has received NMPA approval for PECONDLE® (picankibart injection), China's first domestic IL-23p19 monoclonal antibody for adults with moderate-to-severe plaque psoriasis.

Backed by the CLEAR-1 Phase 3 study, where over 80% of participants achieved PASI 90 at Week 16, PECONDLE® also offers the longest maintenance dosing interval among comparable biologics in China. This milestone brings a new level of skin clearance, quality-of-life improvement, and dosing convenience to patients. It marks an encouraging step forward in expanding access to next-generation precision therapies for psoriasis in China.https://www.prnewswire.com/news-releases/chinas-first-domestic-il-23p19-monoclonal-antibody-innovents-pecondle-picankibart-injection-received-nmpa-approval-302627980.html?tc=eml_cleartime

We're pleased to share that China's NMPA has accepted the supplementary application for mazdutide 9 mg for long-term wei...
26/11/2025

We're pleased to share that China's NMPA has accepted the supplementary application for mazdutide 9 mg for long-term weight management in adults with moderate to severe obesity. As a GCG/GLP-1 dual receptor agonist, mazdutide has the potential to offer a highly effective, safe, and non-invasive treatment option beyond current standard-of-care surgery. This milestone underscores the significant unmet need in obesity care and our commitment to advancing impactful therapies for patients in China. https://www.prnewswire.com/news-releases/mazdutide-9mg-supplementary-application-accepted-for-review-by-chinas-nmpa-potentially-offering-a-novel-drug-option-for-moderate-to-severe-obese-population-302625421.html?tc=eml_cleartime

We're grateful to share that Innovent has been added to the Hang Seng Index, along with the Hang Seng China Enterprises ...
24/11/2025

We're grateful to share that Innovent has been added to the Hang Seng Index, along with the Hang Seng China Enterprises Index and the Hang Seng ESG Enhanced Index—an important milestone as we continue our journey from a biotech startup to a biopharma company recognized by global capital markets. This recognition reflects the collective work behind our innovation engine and diversified pipeline across oncology, cardiovascular and metabolism, autoimmune and ophthalmology, as well as our ongoing commitment to delivering meaningful clinical and operational value. Looking ahead, we remain focused on serving patients and communities while deepening our collaboration with global investors to advance high-quality biopharmaceutical innovation. https://www.prnewswire.com/news-releases/innovent-biologics-enters-hang-seng-index-and-two-other-major-indices-global-capital-markets-recognize-leading-innovators-value-302624043.html?tc=eml_cleartime

Address

Suzhou
215028

Telephone

+8651269566088

Website

Alerts

Be the first to know and let us send you an email when Innovent Biologics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Innovent Biologics:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category